無料セミナー : 2018年11月27日『オンコロジーにおける遺伝子治療・CAR-T細胞療法』 DelveInsight Business Research LLP共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の潰瘍性大腸炎 (UC) 市場:機会分析と産業予測

Ulcerative Colitis Market by Molecule Type, by Disease Type, by Route of Administration - Global Opportunity Analysis and Industry Forecast, 2017-2023

発行 Allied Market Research 商品コード 563282
出版日 ページ情報 英文 150 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
世界の潰瘍性大腸炎 (UC) 市場:機会分析と産業予測 Ulcerative Colitis Market by Molecule Type, by Disease Type, by Route of Administration - Global Opportunity Analysis and Industry Forecast, 2017-2023
出版日: 2017年09月01日 ページ情報: 英文 150 Pages
概要

当レポートでは、世界の潰瘍性大腸炎 (UC) 市場について調査分析し、市場概要、セグメント別の市場分析、地域別分析、企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場定義・範囲
  • 主な調査結果
  • ファイブフォース分析
  • 臨床試験
  • 市場シェア分析
  • 市場力学

第4章 潰瘍性大腸炎 (UC) 市場:疾患タイプ別

  • 概要
  • 軽症の潰瘍性大腸炎
  • 中等症の潰瘍性大腸炎
  • 重症の潰瘍性大腸炎

第5章 潰瘍性大腸炎 (UC) 市場:分子タイプ別

  • 概要
  • 小分子
  • 生物製剤

第6章 潰瘍性大腸炎 (UC) 市場:投与経路別

  • 概要
  • 経口
  • 注射

第7章 潰瘍性大腸炎 (UC) 市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第8章 企業プロファイル

  • PFIZER INC.
  • JOHNSON & JOHNSON
  • GLAXOSMITHKLINE PLC
  • ELI LILLY AND CO.
  • SANOFI AVENTIS A/S
  • ASTRAZENECA PLC
  • MERCK & CO. INC.
  • ABBOTT LABORATORIES
  • INDEX PHARMACEUTICALS HOLDING AB
  • EAファーマ
図表

List of Tables

  • TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 2. GLOBAL ULCERATIVE COLITIS MARKET FOR MILD ULCERATIVE COLITIS DISEASE TYPE, BY REGION, 2016-2023 ($MILLION)
  • TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET FOR MODERATE ULCERATIVE COLITIS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET FOR SEVERE ULCERATIVE COLITIS, BY REGION, 2016-2023 ($MILLION)
  • TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET FOR SMALL MOLECULES, BY REGION, 2016-2023 ($MILLION)
  • TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET FOR BIOLOGICS, BY TYPE, 2016-2023 ($MILLION)
  • TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET FOR ORAL ROUTE OF ADMINISTRATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET FOR INJECTABLES ROUTE OF ADMINISTRATION, BY REGION, 2016-2023 ($MILLION)
  • TABLE 11. ULCERATIVE COLITIS MARKET, BY REGION, 2016-2023 ($MILLION)
  • TABLE 12. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 13. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 14. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 15. NORTH AMERICA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 16. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 17. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 18. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 19. CANADA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 20. U.S. MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 21. CANADA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 22. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 23. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 24. MEXICO MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 25. EUROPE ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 26. EUROPE ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 27. EUROPE ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 28. EUROPE ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 29. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 30. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 31. GERMANY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 32. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 33. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 34. UK MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 35. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 36. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 37. ITALY MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 38. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 39. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 40. FRANCE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 41. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 42. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 43. SPAIN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 44. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 45. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 46. REST OF EUROPE MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 47. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 48. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 51. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 52. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 53. JAPAN MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 54. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 55. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 56. CHINA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 57. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 58. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 59. INDIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 60. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 61. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 62. AUSTRALIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 63. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 64. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 65. SOUTH KOREA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 66. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 69. LAMEA ULCERATIVE COLITIS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
  • TABLE 70. LAMEA ULCERATIVE COLITIS MARKET, BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 71. LAMEA ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 72. LAMEA ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 73. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 74. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 75. SOUTH AFRICA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 76. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 77. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 78. SAUDI ARABIA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 79. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 80. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 81. ISRAEL MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 82. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY DISEASE TYPE, 2016-2023 ($MILLION)
  • TABLE 83. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY MOLECULE TYPE, 2016-2023 ($MILLION)
  • TABLE 84. REST OF LAMEA MARKET SIZE AND FORECAST FOR ULCERATIVE COLITIS MARKET BY ROUTE OF ADMINISTRATION, 2016-2023 ($MILLION)
  • TABLE 85. PFIZER: COMPANY SNAPSHOT
  • TABLE 86. PFIZER: OPERATING SEGMENTS
  • TABLE 87. J&J: COMPANY SNAPSHOT
  • TABLE 88. J&J: OPERATING SEGMENTS
  • TABLE 89. GSK: COMPANY SNAPSHOT
  • TABLE 90. GSK: OPERATING SEGMENTS
  • TABLE 91. ELI: COMPANY SNAPSHOT
  • TABLE 92. ELI: OPERATING SEGMENTS
  • TABLE 93. SANOFI: COMPANY SNAPSHOT
  • TABLE 94. SANOFI: OPERATING SEGMENTS
  • TABLE 95. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 96. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 97. MERCK: COMPANY SNAPSHOT
  • TABLE 98. MERCK: OPERATING SEGMENTS
  • TABLE 99. ABBOTT: COMPANY SNAPSHOT
  • TABLE 100. ABBOTT: OPERATING SEGMENTS
  • TABLE 101. INDEX: COMPANY SNAPSHOT
  • TABLE 102. INDEX: OPERATING SEGMENTS
  • TABLE 103. AJINOMOTO: COMPANY SNAPSHOT
  • TABLE 104. AJINOMOTO: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET, 2016-2023
  • FIGURE 2. SEGMENTATION OF GLOBAL ULCERATIVE COLITIS MARKET, 2016-2023
  • FIGURE 3. TOP INVESTMENT POCKETS IN GLOBAL ULCERATIVE COLITIS MARKET
  • FIGURE 4. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
  • FIGURE 5. BARGAINING POWER OF BUYERS
  • FIGURE 6. BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. THREAT OF NEW ENTRANTS
  • FIGURE 8. THREAT OF SUBSTITUTION
  • FIGURE 9. COMPETITIVE RIVALRY
  • FIGURE 10. RESTRAINTS AND DRIVERS: GLOBAL ULCERATIVE COLITIS MARKET
  • FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET: DISEASE TYPE
  • FIGURE 12. ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE
  • FIGURE 13. ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION
  • FIGURE 14. ULCERATIVE COLITIS MARKET, BY GEOGRAPHY
  • FIGURE 15. PFIZER: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 16. PFIZER: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 17. PFIZER: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 18. J&J: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 19. J&J: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 20. J&J: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 21. GSK: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 22. GSK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 23. GSK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 26. ELI: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 27. ELI: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 28. ELI: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 29. SANOFI: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 30. SANOFI: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 31. SANOFI: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 32. ASTRAZENECA: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 33. ASTRAZENECA: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 34. ASTRAZENECA: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 35. MERCK: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 36. MERCK: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 37. MERCK: REVENUE BY GEOGRAPHY, 2016 (%)
  • FIGURE 38. ABBOTT: NET SALES, 2014-2017 ($MILLION)
  • FIGURE 39. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
  • FIGURE 40. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
目次
Product Code: LI 173965

Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood. As per NCBI, about 1.86 billion patients were diagnosed with UC globally in 2014, with 1.54 billion patients currently receiving treatment. Moreover, it is estimated that in 2015, there were 2.1 million diagnosed cases of UC in U.S., Japan, and five major European countries namely Germany, France, Italy, Spain, and UK. The global ulcerative colitis market accounted for $4,785 million in 2016 and is expected to reach $7,455 million by 2023, registering a CAGR of 6.5% from 2017 to 2023.

The major factors that drive the growth of the global ulcerative colitis market are increasing number of ulcerative colitis patients, new drug formulations by key players, and increasing investments by government and non-government organizations towards research in biologics. However, patent expiry and availability of alternative surgery option for UC treatment restricts the market growth. Conversely, untapped economies are expected to provide lucrative growth opportunities to the market.

The report segments the global ulcerative colitis market based on disease type, molecule type, and route of administration. Based on molecule type, the market is categorized as biologics and small molecules. In terms of disease type, the market is divided into mild, moderate, and severe ulcerative colitis. Based on route of administration, the market is bifurcated into oral and injectables. Regionally, the market is analyzed in North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS:

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global ulcerative colitis market.
  • Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities across the geographies.
  • This report entails the detailed quantitative analysis of the current market and estimations from 2016 to 2023 to identify the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
  • Region- and country-wise ulcerative colitis market conditions are comprehensively analyzed in the report.

KEY MARKET SEGMENTS

By Disease Type

  • Mild Ulcerative Colitis
  • Moderate Ulcerative Colitis
  • Severe Ulcerative Colitis

By Molecule Type

  • Biologics
  • Small Molecules

By Route of Administration

  • Oral
  • Injectables

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • South Korea
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Saudi Arabia
  • South Africa
  • Israel
  • Rest of LAMEA

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2 KEY BENEFITS
    • 1.1.1. Secondary research
    • 1.1.2. Primary research
    • 1.1.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. KEY FINDINGS
    • 3.2.1. Top investment pockets
    • 3.2.2. Top winning strategies
  • 3.3. PORTERS FIVE FORCES ANALYSIS
  • 3.4. CLINICAL TRIALS
  • 3.5. MARKET SHARE ANALYSIS, 2016
  • 3.6. MARKET DYNAMICS
    • 3.6.1. Drivers
      • 3.6.1.1. Growing prevalence of ulcerative colitis disease
      • 3.6.1.2. Increase in R&D and investment by key players towards development of novel drug therapies
      • 3.6.1.3. Rise in government and non-government organization focus towards research in biologics
    • 3.6.2. Restraints
      • 3.6.2.1. Patent expiry of drugs
      • 3.6.2.2. Stringent government regulations towards approval of biosimilars
    • 3.6.3. Opportunities
      • 3.6.3.1. Untapped emerging economies

CHAPTER 4 ULCERATIVE COLITIS, BY DISEASE TYPE

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
  • 4.2. MILD ULCERATIVE COLITIS
    • 4.2.1. Key market trends
    • 4.2.2. Growth factors and opportunities
    • 4.2.3. Market size and forecast
  • 4.3. MODERATE ULCERATIVE COLITIS
    • 4.3.1. Key market trends
    • 4.3.2. Growth factors and opportunities
    • 4.3.3. Market size and forecast
  • 4.4. SEVERE ULCERATIVE COLITIS
    • 4.4.1. Key market trends
    • 4.4.2. Growth factors and opportunities
    • 4.4.3. Market size and forecast

CHAPTER 5 ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE

  • 5.1. OVERVIEW
    • 5.1.1. Market size and forecast
  • 5.2. SMALL MOLECULES
    • 5.2.1. Market size and forecast
  • 5.3. BIOLOGICS
    • 5.3.1. Market size and forecast

CHAPTER 6 ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1. OVERVIEW
    • 6.1.1. Market size and forecast
  • 6.2. ORAL
    • 6.2.1. Market size and forecast
  • 6.3. INJECTABLES
    • 6.3.1. Market size and forecast

CHAPTER 7 ULCERATIVE COLITIS MARKET, BY GEOGRAPHY

  • 7.1. OVERVIEW
    • 7.1.1. Market size and forecast
  • 7.2. NORTH AMERICA
    • 7.2.1. Key market trends
    • 7.2.2. Key growth factors and opportunities
    • 7.2.3. North America Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.2.4. North America Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.2.5. North America Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.2.6. North America Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.1. U.S. Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.2. U.S. Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.3. U.S. Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.4. Canada Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.5. Canada Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.6. Canada Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.2.6.7. Mexico Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.2.6.8. Mexico Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.2.6.9. Mexico Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.3. EUROPE
    • 7.3.1. Key market trends
    • 7.3.2. Key growth factors and opportunities
    • 7.3.3. Europe Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.3.4. Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.3.5. Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.3.6. Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.1. Germany Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.2. Germany Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.3. Germany Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.4. UK Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.5. UK Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.6. UK Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.7. Italy Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.8. Italy Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.9. Italy Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.10. France Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.11. France Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.12. France Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.13. Spain Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.14. Spain Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.15. Spain Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.3.6.16. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.3.6.17. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.3.6.18. Rest of Europe Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.4. ASIA-PACIFIC
    • 7.4.1. Key market trends
    • 7.4.2. Key growth factors and opportunities
    • 7.4.3. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.4.4. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.4.5. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.4.6. Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.1. Japan Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.2. Japan Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.3. Japan Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.4. China Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.5. China Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.6. China Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.7. India Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.8. India Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.9. India Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.10. Australia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.11. Australia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.12. Australia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.13. South Korea Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.14. South Korea Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.15. South Korea Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.4.6.16. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.4.6.17. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.4.6.18. Rest of Asia-Pacific Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
  • 7.5. LAMEA
    • 7.5.1. Key market trends
    • 7.5.2. Key growth factors and opportunities
    • 7.5.3. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Country
    • 7.5.4. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
    • 7.5.5. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
    • 7.5.6. LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.1. South Africa Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.2. South Africa Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.3. South Africa Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.4. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.5. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.6. Saudi Arabia Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.7. Israel Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.8. Israel Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.9. Israel Market Size and Forecast for Ulcerative Colitis Market by Route of Administration
      • 7.5.6.10. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Disease Type
      • 7.5.6.11. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Molecule Type
      • 7.5.6.12. Rest of LAMEA Market Size and Forecast for Ulcerative Colitis Market by Route of Administration

CHAPTER 8 COMPANY PROFILES

  • 8.1. PFIZER INC.
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Business performance
    • 8.1.5. Key strategic moves and developments
  • 8.2. JOHNSON & JOHNSON
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Business performance
    • 8.2.5. Key strategic moves and developments
  • 8.3. GLAXOSMITHKLINE PLC
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
    • 8.3.5. Key strategic moves and developments
  • 8.4. ELI LILLY AND CO.
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
    • 8.4.5. Key strategic moves and developments
  • 8.5. SANOFI AVENTIS A/S
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
    • 8.5.5. Key strategic moves and developments
  • 8.6. ASTRAZENECA PLC
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
    • 8.6.5. Key strategic moves and developments
  • 8.7. MERCK & CO. INC.
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
    • 8.7.5. Key strategic moves and developments
  • 8.8. ABBOTT LABORATORIES
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
    • 8.8.5. Key strategic moves and developments
  • 8.9. INDEX PHARMACEUTICALS HOLDING AB
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Key strategic moves and developments
  • 8.10. AJINOMOTO PHARMACEUTICALS CO., LTD.
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Key strategic moves and developments
Back to Top